VanEck Biotech ETF

BBH · ETF

$246.57−$1.83 (−0.74%)TodayMarket closed ·
Prev close $248.41

About BBH

BBH was created on 2011-12-20 by VanEck. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 482.46m in AUM and 26 holdings. BBH tracks a market-cap-weighted index of the 25 largest biotech firms globally.

Issuer
VanEck
Tracks
MVIS US Listed Biotech 25
Expense ratio
0.35%
Assets under management
$509.44M
Inception
Dec 20, 2011
Asset class
Equity
Website
vaneck.com

BBH key statistics

Market cap
0
Price-earnings ratio
0.00
Average volume
12.29K
Volume
4.97K
Open price
$247.53
High today
$247.69
Low today
$246.05
52 Week high
$251.45
52 Week low
$176.30

VanEck Biotech ETF (BBH) at a glance

As of Oct 23, 2026, VanEck Biotech ETF (BBH) shares are priced at $246.57, giving the company a market cap of 0 and a price-to-earnings ratio of 0.00.

Today the fund has traded between $246.05 and $247.69. The current price is 0.2% above the day's low and 0.5% below its high.

Volume so far is 4.97K shares, below the average of 12.29K shares a day.

Over the past year VanEck Biotech ETF has ranged from $176.30 to $251.45, and now sits 94% of the way up that range.

BBH news

  • Reported October 22, U.S. Treasury Department Issues Notice Of Proposed Rulemaking For The Outbound Investment Security Program Under The COINS Act; Secretary Has Added Biotechnology To Proposed Regulations

  • Press releaseBusiness Wire

    VanEck Announces Year-End Distributions for VanEck Equity ETFs

  • Press releaseBusiness Wire

    VanEck Announces Year-End Distributions for VanEck Equity ETFs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.